SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical ...
Ipsen made the decision to terminate its deal with Sutro Biopharma “following the review of new data and developments in the ROR1 landscape,” according to Sutro ...
SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the ...
Researchers report that an oncogene dubbed ROR1, found on chronic lymphocytic leukemia (CLL) B cells but not normal adult tissues, acts as an accelerant when combined with another oncogene, resulting ...
Tumor-initiating cells, or cancer stem cells, are gaining attention in cancer therapy, as they can travel through the body and cause cancerous tumors at other sites through metastasis. These cells ...
SAN DIEGO--(BUSINESS WIRE)--VelosBio Inc. (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
- Zentalis to receive up-front payment of $35 million in cash and Immunome common stock and is eligible to receive up to $275 million of milestone payments and mid-to-high single-digit royalties - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results